Cristian Massacesi, Executive Vice President, Chief Medical Officer and Head of Development at Bristol Myers Squibb, shared a post on LinkedIn:
“Over the course of my career working in oncology, I’ve attended many, many ASCO Annual Meetings. But my first as Chief Medical Officer and Head of Development at Bristol Myers Squibb has been a truly special one.
The science spoke loudly. BMS brought more than 60 data disclosures and 19 oral presentations to ASCO this year, spanning hematologic malignancies and solid tumors, across more than 10 cancer types. The breadth and depth of our pipeline — from our targeted protein degradation platform, where BMS is leading the field, to a bispecific ADC that has now shown clinical benefit across three Phase 3 trials in hard-to-treat cancers, to a next-generation approach with the potential to become a new backbone in immuno-oncology — reflects something I genuinely believe: we are at an inflection point in what is possible for patients with cancer.
The conversation mattered just as much. Some of the most meaningful moments this week didn’t happen on a podium. They happened in hallways and meeting rooms, with the academic partners and collaborators who are on the front lines of cancer care every day. These are the people who tell us what patients need. Listening to them, and building relationships that will last beyond this week, is what makes ASCO what it is.
And then there was AI. During an OncoDaily Grand Rounds panel, I participated in a conversation on the expanding role of AI in oncology alongside Douglas Flora, Pavan Anné, Debra Patt, Sanjay Juneja, and Sunil Verma. My takeaway: efficiency is the floor, not the ceiling. AI is already changing how we design trials, select patients, and develop medicines faster — but the real prize is predictive AI that shifts decisions earlier, with greater confidence. The bottleneck today isn’t data. It’s translating data into accountable decisions at scale.
I’m grateful to the BMS team, our partners across academia and industry, and, most of all, to the patients we serve.
Onward. There is still so much to do.”
Other articles featuring Cristian Massacesi on OncoDaily.
